2,6-二甲基-4-羟基吡啶 | 13603-44-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,6-二甲基-4-羟基吡啶
• 中文别名: 4-羟基-2,6-二甲基吡啶；2,6-二甲基-4-吡啶醇
• 英文名称: 2,6-dimethylpyridin-4-ol
• 英文别名: 2,6-dimethyl-4-hydroxypyridine；4-hydroxy-2,6-dimethylpyridine；2,6-Dimethyl-4-hydroxy-pyridin；2,6-dimethyl-1H-pyridin-4-one
• CAS: 13603-44-6
• 化学式: C₇H₉NO
• mdl: MFCD00956021
• 分子量: 123.155
• InChiKey: PRAFLUMTYHBEHE-UHFFFAOYSA-N

物化性质

• 熔点：
  230-232°C
• 沸点：
  351 °C
• 密度：
  1,053g/cm
• 溶解度：
  DMSO（微溶，加热）、甲醇（微溶）
• LogP：
  0.190 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  29333990
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温条件下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,6-Dimethyl-4-hydroxypyridine
Synonyms: 2,6-Dimethylpyridin-4-ol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,6-Dimethyl-4-hydroxypyridine
CAS number: 13603-44-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9NO
Molecular weight: 123.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2,6-二甲基-4-羟基吡啶在养殖业中是防治家禽和家畜球虫病的特效药及饲料添加剂。除了具有防治球虫病的效果外，它还能显著促进家禽的生长发育，并明显提高饲料的转化利用率。

制备

将 40 mL N,N-二甲基甲酰胺（DMF）与 33.6 g (0.2 mol) 脱氢醋酸加入到 500 mL 三口烧瓶中，随后加入 40 mL 质量分数为 25% 的氨水。在室温下反应 10 小时后，析出白色结晶。加热并搅拌，回流 14 小时，再补加适量氨水。常压下蒸出部分反应液，在 128~150 ℃ 下继续反应 10 小时。冷却后，将析出的晶体通过真空过滤分离，并在干燥条件下得到 2,6-二甲基-4-羟基吡啶 20 g，产率为 81.3%，熔点为 216~218 ℃。

反应信息

• 作为反应物：
  描述：

  2,6-二甲基-4-羟基吡啶 生成 2,6-二甲基吡啶
  参考文献：
  名称：

  Haitinger, Chemische Berichte, 1885, vol. 18, p. 452

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-2,6-二甲基吡啶 在 sodium acetate 、 溶剂黄146 作用下， 生成 2,6-二甲基-4-羟基吡啶
  参考文献：
  名称：

  Ochiai; Fujimoto, Pharmaceutical Bulletin, 1954, vol. 2, p. 131,136

  摘要：

  DOI：
• 作为试剂：
  描述：

  (S)-isopropyl 2-(tert-butoxy)-2-(4-(chroman-6-yl)-2-methyl-6-(3-(tetrahydro-2H-pyran-4-yl)propyl)-5-(1,2,3,4-tetrahydroisoquinolin-6-yl)pyridin-3-yl)acetate 、 2-氟-6-甲基苯甲醛 在 三乙胺 、 2,6-二甲基-4-羟基吡啶 、 三乙酰氧基硼氢化钠 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以76%的产率得到(S)-2-(tert-butoxy)-2-(4-(chroman-6-yl)-5-(2-(2-fluoro-6-methylbenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-6-(3-(tetrahydro-2H-pyran-4-yl)propyl)pyridin-3-yl)acetic acid
  参考文献：
  名称：

  [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  [FR] DÉRIVÉS DE L'ACIDE PYRIDIN-3-YL-ACÉTIQUE UTILISÉS COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE

  摘要：

  揭示了公式I的化合物，包括药用可接受的盐，包含这些化合物的药物组合物，制备这些化合物的方法以及它们在抑制HIV整合酶和治疗HIV或艾滋病感染者中的用途。

  公开号：

  WO2017029631A1

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243527A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性核上性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。
• [EN] N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG<br/>[FR] DÉRIVÉS DE N-ACYLHYDRAZONE DESTINÉS À UN MÉDICAMENT ANTIMALIGNITÉ LYMPHOÏDE ET INHIBANT SÉLECTIVEMENT LES LYMPHOCYTES T
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2014035149A1

  公开（公告）日：2014-03-06

  The present invention relates to novel N-acylhydrazone derivatives, and more particularly to novel N-acylhydrazone derivatives having selective T cell inhibitory activity and/or anti-lymphoid malignancy activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, treatment methods using the compositions, and methods for preparing the novel N-acylhydrazone derivatives.

  本发明涉及新型的N-酰腙衍生物，特别是具有选择性的T细胞抑制活性和对淋巴细胞恶性肿瘤的活性的新型N-酰腙衍生物，其立体异构体，可药用的盐，以及使用它们来制备药物组合物，包含它们的药物组合物，使用该组合物的治疗方法，以及制备新型N-酰腙衍生物的方法。
• Heterocyclic Compound
  申请人：Amasaki Ichiro

  公开号：US20100004439A1

  公开（公告）日：2010-01-07

  A compound represented by the following Formula (1): wherein, Het 1 represents a bivalent five- or six-membered aromatic heterocyclic residue and may further be substituted; X a to X d each independently represent a heteroatom and may further be substituted; Y a to Y f each independently represent a heteroatom or a carbon atom and may further be substituted; the ring bound to Het 1 may have a double bond at any position

  以下是您提供的化学公式(1)的中文翻译： 其中，Het1代表一个二价的五元或六元芳香杂环基团，且可以进一步被取代；Xa至Xd每个独立地代表一个杂原子，且可以进一步被取代；Ya至Yf每个独立地代表一个杂原子或一个碳原子，且可以进一步被取代；与Het1相连的环可以在任何位置有一个双键。
• Novel Compounds
  申请人：Gottschling Dirk

  公开号：US20120088755A1

  公开（公告）日：2012-04-12

  The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R 1 , R 2 and R 3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的新化合物，其中A、U、V、X、Y、R1、R2和R3的定义如下所述，其互变异构体、异构体、二对映异构体、对映体、水合物、混合物及其盐以及该盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，含有这些化合物的药物，它们的用途以及制备它们的方法。
• PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：Bristol-Myers Squibb Company

  公开号：US20150232463A1

  公开（公告）日：2015-08-20

  The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及公式I、II、III和IV的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。